CurrentBlue Cross Blue Shield - TennesseePolicy N/A

Nerve Fiber Density Testing (IENFD/ENFD)

Policy governing coverage of epidermal (intraepidermal) nerve fiber density testing from skin biopsy for diagnosis of small-fiber neuropathy and related assays; excludes sweat gland nerve fiber density testing. Applies to Blue Cross Blue Shield - Tennessee members.

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyNerve Fiber Density Testing (IENFD/ENFD) - coverage of skin biopsy measurement for small-fiber neuropathy diagnosis

Policy CodePolicy N/A

Change TypeNo material clinical or coverage changes

Effective DateN/A

Next Review DateN/A

Key ActionObtain and document guideline-based clinical findings and prior non-diagnostic nerve conduction studies when requesting prior authorization for epidermal nerve fiber density testing.

SourceLink

POLICY UPDATE CHANGES

No material clinical or coverage changes in this revision.

<8/mmIENF cutoff cited

95%–97%Specificity

45%–90%Sensitivity range

Sweat gland testingNot covered

≈35,000Biopsies reported

Trek Health ingests and normalizes Transparency in Coverage data and payer policy updates to give provider organizations a clear view of how commercial reimbursement behaves across markets, payers, and services. Our platform transforms raw payer disclosures into structured intelligence that supports contract evaluation, payer negotiations, and service line strategy. By combining market benchmarks with ongoing policy visibility, Trek helps teams identify variability, risk, and opportunity in commercial reimbursement. The result is faster insight, stronger negotiating positions, and more informed financial decisions.

Coverage Criteria for Nerve Fiber Density Testing

Covered: Diagnosis of small-fiber neuropathy (IENFD)

Epidermal nerve fiber density measurement from a skin biopsy MEETS COVERAGE CRITERIA when ALL of the following are met:

Diagnosis of small-fiber neuropathy coverage criteria: a) An individual presents with symptoms of painful sensory neuropathy; b) There is no history of a disorder known to predispose to painful neuropathy (e.g., diabetic neuropathy, toxic neuropathy, HIV neuropathy, celiac neuropathy, inherited neuropathy); c) Physical examination shows no evidence of findings consistent with large-fiber neuropathy, such as reduced or absent muscle-stretch reflexes or reduced proprioception and vibration sensation; d) Electromyography and nerve-conduction studies are normal and show no evidence of large-fiber neuropathy.all four required

These four conditions must all be present for coverage.

Not medically necessary / Not covered

Not covered situations

Other indications: Measurement of epidermal nerve fiber density from skin biopsy for situations not meeting the above criteria.any

Does not meet coverage criteria.

Sweat gland nerve fiber density: Measurement of sweat gland nerve fiber density.any

Does not meet coverage criteria; explicitly not covered.

Medically necessary criteria

Covered when aligned with guideline-supported indications and clinical context

Guideline-aligned indication: Clinical suspicion of small fiber neuropathy or distal symmetric polyneuropathy (e.g., painful/burning feet, autonomic dysfunction) or situations where biopsy aids diagnosis (e.g., suspected amyloid neuropathy, atypical neuropathies).

Supported by AAN/AANEM/AAPM&R Level C and EFNS/PNS guidance.

Prior noninvasive assessment: Prior non-diagnostic nerve conduction studies or appropriate bedside/functional testing when applicable (e.g., 10-g monofilament, 128-Hz tuning fork, autonomic testing).

Per AACE/ACE and ADA guidance; biopsy may be used when clinical suspicion remains despite prior testing.

Guideline-based clinical roles

Guidelines and expert panels referenced state clinical roles for skin biopsy/IENFD:

Diagnostic use: Skin biopsy with quantification of IENFD is recommended as a reliable method to assess small fiber neuropathy and should be performed in patients with clinical signs of small fiber dysfunction or painful/burning feet of unknown origin.

Supported by EFNS/PNS (grade B) and NeuPSIG (level B).

Monitoring and research: IENFD measurement may be used for follow-up and to detect treatment response in diabetic patients with small fiber neuropathy and is used in research and clinical trials to measure small fiber damage and repair.

Supported by IMMPACT and Haanpaa et al. statements (level C for monitoring).

Limitations: IENFD correlates only weakly with pain severity and does not identify etiology of SFN; it should not be used alone to measure pain intensity in individual patients.

EFNS and IMMPACT caution regarding weak correlation with pain intensity and limitations in etiologic diagnosis.

Measurement of sweat gland nerve fiber density (SGNFD / SGII) from skin biopsy does not meet coverage criteria. Although research methods have been developed to quantify sweat gland innervation and these measures may correlate with sudomotor symptoms in diabetes, the policy explicitly excludes sweat gland nerve fiber density measurement from coverage and notes that skin biopsy cannot determine etiology of neuropathy or replace nerve biopsy when mixed or large‑fiber processes or vasculitis are suspected.

Skin biopsy has limited diagnostic utility for erythromelalgia. In a retrospective series, fewer than 10% of erythromelalgia patients showed decreased epidermal nerve fiber density, and the authors concluded that skin biopsy is not useful for diagnosing this condition. For other pain syndromes such as fibromyalgia, studies report mixed findings and skin biopsy cannot reliably distinguish patients by pain intensity; therefore biopsy is generally not appropriate as the primary diagnostic test for erythromelalgia.

For Fabry disease, nerve or skin biopsy is not required for diagnosis because accurate laboratory diagnostic tests are available. The international expert panel notes that skin biopsy can detect small‑fiber involvement in asymptomatic patients or be used to quantify skin innervation in select contexts, but biopsy is not necessary for establishing the diagnosis.

References caution that small‑fiber morphometric assessments have limitations for confirming specific genetic diagnoses. For example, assessments of small fiber innervation may not confirm nonclassical or variant forms of Fabry disease, and the literature includes reports that small fiber testing alone cannot establish a genetic diagnosis; such limitations should be considered when interpreting biopsy results in hereditary or atypical presentations.

Epidermal nerve fiber density measurement from skin biopsy is covered only for the diagnosis of small‑fiber neuropathy when the policy's specified clinical criteria are met. Use of IENFD testing for indications other than diagnosis of small‑fiber neuropathy that meet those criteria is not routinely covered and does not meet coverage criteria.

Routine use of skin biopsy solely to measure pain intensity is not supported. Guideline panels (EFNS/PNS, IMMPACT) report that IENFD correlates only weakly with pain severity, and additional research is needed before IENFD can be used as a biomarker of pain; therefore skin biopsy should not be used as a routine tool to quantify pain alone.

IENFD should not be used alone to measure pain severity in individual patients. Expert guidance indicates only weak correlations between IENFD and pain intensity, so interpretation of biopsy results requires integration with the clinical context and other diagnostic tests rather than reliance on IENFD as a standalone measure of pain.

Procedure and Test Coding

Procedure CPT CodesCPT

88313	Special stain including interpretation and report; Group II, all other (eg, iron, trichrome), except stain for microorganisms, stains for enzyme constituents, or immunocytochemistry and immunohistochemistry.
88341	Immunohistochemistry or immunocytochemistry, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure).
88342	Immunohistochemistry or immunocytochemistry, per specimen; initial single antibody stain procedure.
88344	Immunohistochemistry or immunocytochemistry, per specimen; each multiplex antibody stain procedure.
88346	Immunofluorescence, per specimen; initial single antibody stain procedure.
88350	Immunofluorescence, per specimen; each additional single antibody stain procedure (List separately in addition to code for primary procedure).
88356	Morphometric analysis; nerve

inv-13: IENF cutoff at dorsal foot

IENF cutoff (dorsal foot)< 8 fibers/mm (provides sensitivity 88% and specificity 91% for SFSN in patients with abnormal pinprick but normal reflexes/vibration/NCS)

Supporting studyEngland et al., 2009b summarized in policy — 4 studies at ankle with specificity 95%–97.5% and sensitivities 24%–100%

Normative referenceCollongues et al. normative formula for distal leg IENFD (5th percentile): 7.6156 - 0.0769 × age + 1.5506 × gender (woman=1; man=0)

inv-14: Inter-fiber denervated stretch

Inter-fiber denervated stretch threshold> 350 µm (a stretch of denervated epidermis >350 µm increased diagnostic efficiency; AUC=0.85, sensitivity 74%, specificity 94%)

Study context

Provider Requirements, Authorization & Documentation

Prior Authorization

Prior Authorization Required

Prior Authorization Required — Epidermal nerve fiber density measurement from skin biopsy requires prior authorization when used to diagnose small-fiber neuropathy per the policy coverage criteria. Authorization requests should cite guideline-based indications and include required clinical documentation to support medical necessity.

Prior authorization required for diagnostic testing of suspected small-fiber neuropathy.
Include references to guideline-based indications (eg, suspected distal symmetric small fiber neuropathy; painful/burning feet of unknown origin; distal symmetric polyneuropathy with normal NCS/EMG).

Documentation Required

Required Clinical Documentation

Documentation — Providers must submit comprehensive clinical documentation with authorization requests. Documentation should demonstrate the clinical presentation, prior evaluations, and absence of an alternative disorder that commonly predisposes to neuropathy.

Background and Test Description

BACKGROUND: Skin punch biopsy with PGP 9.5 immunostaining quantifies intraepidermal (epidermal) nerve fiber density (IENFD) and is a minimally invasive, reliable technique to evaluate small‑fiber sensory and autonomic neuropathy. Guidelines recommend distal leg (ankle) 3‑mm biopsy with standardized counting rules as an efficient method to assess small‑fiber neuropathy, though the test does not identify etiology and cannot replace nerve biopsy when large‑fiber disease or vasculitis is suspected.

Definitions and Key Terms

inv-32: IENF / ENFD definition

DefinitionIntraepidermal (epidermal) nerve fiber density (IENF/ENFD) — number and morphology of axons within the epidermis measured on skin biopsy stained with PGP 9.5

Measurement siteTypically performed on distal leg (ankle) biopsies using 3-mm punch specimens per guideline recommendations

PurposeQuantifies small sensory nerve fibers to assess presence and degree of small-fiber sensory neuropathy

inv-33: SGNFD / SGII / Sweat gland innervation index

DefinitionSweat gland nerve fiber density measures (SGNFD / SGII / sweat gland innervation index) quantify sudomotor innervation in skin biopsies

Technique notesMethods include PGP 9.5 staining and stereologic or modified staining approaches to calculate SGNFD or SGII

Policy Summary

PayerBlue Cross Blue Shield - Tennessee

PolicyNerve Fiber Density Testing (IENFD/ENFD) - coverage of skin biopsy measurement for small-fiber neuropathy diagnosis

Policy CodePolicy N/A

Change TypeNo material clinical or coverage changes

Effective DateN/A

Next Review DateN/A

Key ActionObtain and document guideline-based clinical findings and prior non-diagnostic nerve conduction studies when requesting prior authorization for epidermal nerve fiber density testing.

SourceLink

On This Page

Piscosquito et al. (2021): compared SFN patients, controls, and patients with normal counts but abnormal QST; identified 350 µm as optimal cutpoint

Clinical implicationInter-fiber denervated stretch may complement IENFD counts to improve biopsy diagnostic yield when counts alone are inconclusive

Document symptoms of painful sensory neuropathy (eg, burning, tingling, lancinating pain).

Document absence of disorders known to predispose to peripheral neuropathy (eg, diabetes, toxic exposures, HIV, celiac disease, inherited neuropathy).

Document prior assessments including neurologic exam and results of nerve conduction studies/electromyography.

Note

Guideline-based Indication and Initial Evaluation

Clinical Indications and Evaluation Steps — Testing should follow guideline-based clinical evaluation. Noninvasive bedside and functional testing are recommended components of the initial evaluation prior to biopsy.

Perform thorough history and focused exam assessing small- and large-fiber function.
Use bedside tests: 10-g monofilament, 128-Hz tuning fork for vibration, and pinprick/temperature testing.
Consider autonomic testing indices and other functional tests where clinically indicated.
Reserve skin biopsy for patients with clinical suspicion of small-fiber neuropathy and normal/ nondiagnostic nerve conduction studies and EMG.

Billing Rule

Billing and Laboratory Validation

Billing and Laboratory Validation — Laboratories performing skin biopsy analysis typically use laboratory-developed tests (LDTs) that are regulated under CLIA as high-complexity tests. FDA clearance is not required for LDTs, but labs must validate and perform tests in-house per CLIA requirements.

LDTs for epidermal nerve fiber density are CLIA-regulated high-complexity tests; ensure the performing laboratory is CLIA-certified.
FDA approval/clearance is not required for LDT clinical use, but validation records should be available upon request.

Billing Rule

Coding and Reporting

Coding and Reporting — Use appropriate pathology and immunohistochemistry CPT/HCPCS procedure codes when billing for skin biopsy processing and analysis.

Relevant procedure codes include (but may not be limited to): 88313, 88341, 88342, 88344, 88346, 88350, 88356.
Ensure accurate reporting of performed stains, morphometric analysis, and interpretation in the pathology report.

Denial Risk

Low-Yield and Not-Covered Indications

Low-Yield and Not-Covered Indications — Skin biopsy has limited utility for certain conditions and some tests are explicitly non-covered.

Skin biopsy is of limited diagnostic yield for erythromelalgia; testing for this indication may be denied.
Measurement of sweat gland nerve fiber density does NOT meet coverage criteria and is not covered.

Note

Conflict with Government Policy

Conflict with Government Policy — If state or federal (eg, Medicare/Medicaid) policies conflict with this policy for a particular member, the applicable government policy will govern coverage determinations.

When a Local Coverage Determination (LCD), National Coverage Determination (NCD), or state Medicaid policy applies, that policy supersedes this payer policy for the affected member.

Note

Authorization Notes & Supporting Documentation

Authorization Notes and Supporting Documentation — Provide supporting literature and references where relevant; standard clinical references may be used to support the request but do not replace required patient-specific documentation.

Attach pertinent guideline excerpts or literature citations (eg, EFNS/PNS, AAN, ADA, AACE) when helpful to support testing rationale.
Supporting references (eg, UpToDate, peer-reviewed studies) may be included but the request must focus on the member’s clinical data and prior evaluations.

Step Therapy

Step Therapy — No step therapy requirements are specified for epidermal nerve fiber density measurement; clinical pathway should follow guideline-driven evaluation and appropriate prior testing.

No mandated step therapy or prerequisite treatments are required by this policy section beyond the recommended clinical and diagnostic evaluation steps.

Coverage stanceMeasurement of sweat gland nerve fiber density is explicitly noted as not meeting coverage criteria in this policy (not covered)

inv-34: Intraepidermal nerve fiber density (IENFD)

DefinitionIntraepidermal nerve fiber density (IENFD) — linear density of small unmyelinated nerve fibers in distal leg skin biopsy, counted using generally agreed counting rules

Clinical correlationIENFD inversely correlates with cold and heat detection thresholds and is reduced in symptomatic patients with normal nerve conduction studies

Guideline endorsementEFNS/PNS and other societies endorse distal leg IENFD quantification as a reliable method to assess SFN

inv-35: IENFD

Alternate wordingIENFD — the linear density of small nerve fibers in the epidermis quantified from a distal leg skin biopsy used to diagnose small fiber neuropathy

Procedure safety3-mm distal leg biopsy is considered safe based on experience reporting ~35,000 biopsies with no serious side effects and 0.19% non-serious side effects

LimitationsIENFD does not identify etiology of SFN and correlates only weakly with pain intensity

inv-36: LDT

DefinitionLaboratory-developed test (LDT) — a test developed and validated within a laboratory and regulated under CLIA as a high-complexity test (not FDA-cleared)

Regulatory contextLDTs used for skin biopsy analysis must be validated by the performing laboratory and are regulated by CMS under CLIA '88 as high-complexity tests

Billing noteFDA clearance is not required for clinical use of LDTs but laboratories must follow CLIA validation and reporting requirements

inv-37: intraepidermal nerve fiber density (IENFD)

Normative contextNormative IENFD equations and reference ranges are available (e.g., Collongues et al. distal leg 5th percentile formula) to interpret results

Diagnostic performanceAn IENF density <8 fibers/mm at the dorsal foot corresponds to high sensitivity/specificity in select cohorts; studies report wide sensitivity (24%–100%) and high specificity (95%–97.5%)

Use in interpretationUse age- and sex-adjusted normative values and validated counting rules when classifying IENFD as abnormal

inv-38: sudomotor/sweat gland innervation quantitation

AssessmentSudomotor/sweat gland innervation quantitation evaluates autonomic small fiber function by measuring innervation of sweat glands in skin biopsy specimens

MethodsTechniques include specialized staining (PGP 9.5 +/- counterstains) and stereologic or index calculations (SGNFD, SGII) described in the literature

Policy implicationAlthough useful in research and correlation with autonomic symptoms, sweat gland innervation measures are not covered by this policy